Neoplasms

Blood and Lymph Conditions

All Conditions

Rare Diseases

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Neoplasms by Histologic Type

Hematologic Diseases

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Several tested doses of UCART123 until the Maximum Tolerated Dose (MTD) is identified.

Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor

UCART123

Ghulam Mufti, Pr

This is a Phase I, open-label, dose escalation study of UCART123 administered intravenously to patients with newly diagnosed CD123 positive adverse genetic risk acute myeloid leukaemia (AML) defined in the ELN adverse genetic risk group (2017). The purpose of this study is to evaluate the safety and clinical activity of multiple infusions of UCART123 and to determine the Maximum Tolerated Dose (MTD).

Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia

Phase I, Open Label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of Multiple Infusions of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor) in Patients With Adverse Genetic Risk Acute Myeloid Leukaemia

Incidence, nature, and severity of adverse events and serious adverse events (SAEs) throughout the study

Cellectis S.A.

Immune System Diseases

Lymphoma

Hematologic Neoplasms

Lymphosarcoma

Dendritic Cell Tumor

Blastic Plasmacytoid Dendritic Cell

A single intravenous administration of UCART123. Dose escalation in Part 1 will include 3 doses ranging from 6.25 x 10\^5 cells/kg to 6.25 x 10\^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.

A single intravenous administration of UCART123 at the RP2D. 2 Cohorts: Patients with Relapsed/Refractory BPDCN and Newly Diagnosed BPDCN.

Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.

Ioana Kloos, MD

A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), followed by a dose expansion phase in relapsed or refractory BPDCN patients or newly diagnosed BPDCN patients.

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

Phase 1, Open-label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of a Single Dose of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia	NCT04106076	Acute Myeloid L...	UCART123	18 Years - 65 Years	Cellectis S.A.
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN	NCT03203369	Blastic Plasmac...	UCART123	18 Years - 80 Years	Cellectis S.A.
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN	NCT03203369	Blastic Plasmac...	UCART123	18 Years - 80 Years	Cellectis S.A.

Spots Global Cancer Trial Database for ucart123

Every month we try and update this database with for ucart123 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ucart123

Every month we try and update this database with for ucart123 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ucart123 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.